

### ***Amendments to the Claims***

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-40 (cancelled).

Claim 41 (previously presented): An isolated peptide less than 15 amino acids in length comprising the oligopeptide KVAELVHFL (SEQ ID NO:711).

Claim 42-48 (cancelled).

Claim 49 (withdrawn): A composition comprising the peptide of claim 41, wherein said peptide is linked to a T helper peptide.

Claim 50 (currently amended): A composition comprising the peptide of claim 41, wherein said peptide is linked to a spacer or linker ~~amino acids~~, wherein said spacer or linker is between one and six amino acids in length.

Claim 51 (withdrawn): A composition comprising the peptide of claim 41, wherein said peptide is linked to a carrier.

Claim 52 (withdrawn): A composition comprising the peptide of claim 41, wherein said peptide is linked to a lipid.

Claim 53 (cancelled).

Claim 54 (withdrawn): A homopolymer of the peptide of claim 41.

Claim 55 (withdrawn-currently amended): A heteropolymer of the peptide of claim 41 and at least one different peptide, wherein said at least one different peptide is not derived from MAGE 3 and is a cytotoxic T cell (CTL)- inducing peptide or a helper T cell (HTL)- inducing peptide.

Claim 56 (previously presented): A composition comprising the peptide of claim 41 and a carrier.

Claim 57 (previously presented): A composition comprising the peptide of claim 41 and a pharmaceutically acceptable carrier.

Claim 58 (withdrawn): A composition comprising the peptide of claim 41 and a liposome.

Claim 59 (currently amended): A composition comprising the peptide of claim 41, and one or more different isolated peptides, wherein said one or more different isolated peptide is a cytotoxic T cell (CTL)- inducing peptide or a helper T cell (HTL)- inducing peptide.

Claim 60 (withdrawn): The composition of claim 59, wherein said peptides form a fusion protein.

Claim 61 (previously presented): The composition of claim 59, further comprising a carrier.

Claim 62 (previously presented): The composition of claim 59 further comprising a pharmaceutically acceptable carrier.

Claim 63 (withdrawn-currently amended): The composition of claim 59, wherein said peptides are linked by a spacer or linker ~~amino acids~~, wherein said spacer or linker is between one and six amino acids in length.